Liquid Crystal Pharmaceuticals (LCP^®) are an exciting new area for drug development. In the 1970's early liquid crystal research supported few biological applications. This work was primarily aimed at developing better LCD technologies responsible for today's $60 billion flat screen industry. More recently however, researchers have turned their interests to intricate biological applications of liquid crystals useful in medicine. Together with modern bioinformatics techniques, this has led to the discovery of liquid crystal properties that can more safely target and treat aberrant cells.

The properties of biologically active liquid crystals are complex. However useful mechanisms of action include cell signal inhibition, control of intracellular ROS, cell cycle, gene delivery and regulation of transcription factors responsible for whole banks of genes necessary for regulatory processes. Consequently, LCP's offer the prospect of less toxic, more effective new drugs for the treatment of disease.

IC-MedTech, Inc. is a privately held San Diego biopharmaceutical company engaged in early and mid-stage LCP drug development. The company utilizes commercial drug discovery techniques based on computational and laboratory screening for biologically relevant mesogens. At the nano-scale the unique properties of liquid crystals are known to "switch on" physical, chemical and electronic mechanisms useful for treatment. The company owns exclusive rights to a family of pre-clinical compounds and methods useful as drugs.

IC-MedTech is focused on creating safe, effective, affordable new drugs. Based near San Diego, California the company's lead compounds are clinical phase small molecules that target inflammation.